Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

21 to 40 of 66

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhoea	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Diarrhoea	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Nausea	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Nausea	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	3	34
other	COVID-19	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	COVID-19	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Conjunctivitis	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	1	57
other	Conjunctivitis	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Urinary tract infection	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Urinary tract infection	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Viral infection	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Viral infection	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Gamma-glutamyltransferase increased	Investigations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	1	57
other	Gamma-glutamyltransferase increased	Investigations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Depression	Psychiatric disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Depression	Psychiatric disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	3	34
other	Cough	Respiratory, thoracic and mediastinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Cough	Respiratory, thoracic and mediastinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Upper respiratory tract inflammation	Respiratory, thoracic and mediastinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03648541/events?page=2

API reference For AI assistants